Leaders at life sciences companies appear to be embracing newer digital technologies such as the metaverse, albeit at a varied pace, and for those sitting on the fence, Apple’s entry into the area may perhaps provide a nudge.
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Will Apple’s Move Nudge Undecided?
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.